14103-68-5

Basic information

• Product Name: (3-pentadecylphenoxy)acetic acid
• CAS NO: 14103-68-5
• Molecular Formula: C₂₃H₃₈O₃
• Molecular Weight: 362.546
• Mol File: 14103-68-5.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 484.2°C at 760 mmHg
• Flash Point: 155.2°C
• Density: 0.974g/cm³
• Vapor Pressure: 3.46E-10mmHg at 25°C
• Refractive Index: 1.497
• CAS DataBase Reference: (3-pentadecylphenoxy)acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (3-pentadecylphenoxy)acetic acid(14103-68-5)
• EPA Substance Registry System: (3-pentadecylphenoxy)acetic acid(14103-68-5)

Safety Data

• Hazardous Substances Data: 14103-68-5(Hazardous Substances Data)

Usage

General Description

(3-pentadecylphenoxy)acetic acid, also known as 3-PPA, is a long-chain fatty acid derivative that consists of a pentadecylphenoxy group attached to an acetic acid molecule. It is commonly used as an herbicide and plant growth regulator, inhibiting the growth of weeds and promoting the growth of desired plants. 3-PPA works by interfering with the synthesis of indole-3-acetic acid, a plant hormone essential for growth and development. It is also used in research to study the effects of fatty acid derivatives on plant physiology and metabolism. Additionally, 3-PPA has potential applications in the development of environmentally friendly herbicides due to its natural origin and biodegradability.

Upstream product

• 200133-85-3 ethyl-2-(3-pentadecylphenoxy)acetate 
• 501-24-6 3-n-Pentadecylphenol 
• 105-39-5 chloroacetic acid ethyl ester 
• 501-26-8 3-[(Z)-8-pentadecenyl]phenol 
• 79-11-8 chloroacetic acid 

Relevant articles and documents

Creation of dextrin vesicles and their loading-delivering capabilities

Dextrin vesicles are created, for the first time, by cleverly customizing the polysaccharide backbone with renewable resource 3-pentadecylphenol pendant molecules, which are capable of loading hydrophilic and hydrophobic drugs and subsequently release the

Cisplatin-Stitched Polysaccharide Vesicles for Synergistic Cancer Therapy of Triple Antagonistic Drugs

New cisplatin-stitched polysaccharide vesicular nanocarrier is developed for combination therapy of three clinical important antagonistic drugs together to accomplish synergistic cancer therapy in breast cancer treatment. Carboxylic functionalized dextran was tailor-made for the chemical conjugation of cisplatin, and a renewable hydrophobic unit was anchored in the backbone to interdigitize the chains to self-assemble as cisplatin-stitched polysaccharide nanovesicles. Water-soluble DNA-intercalating drug doxorubicin·HCl (DOX) and water insoluble topoisomerase type I inhibitor drug camptothecin (CPT) were encapsulated in these vesicles to produce dual or triple drug-loaded vesicular nanocarrier. This unique cisplatin, DOX and CPT triple drug-loaded dextran vesicles were stable in aqueous medium, and the vesicular geometry acted as a shield for Pt-polymer drug conjugate against glutathione (GSH) detoxification under physiological conditions. Lysosomal enzymes ruptured the nanovesicle exclusively at the intracellular compartments to deliver the combination of all three drugs simultaneously to maximize the therapeutic efficacies. In vitro cytotoxicity studies revealed that free cisplatin was highly detoxified by the GSH in breast cancer cells, whereas the enhanced stability of Pt-stitched dextran vesicle against GSH facilitated ～99% cell killing in breast cancer cells. Combination therapy studies revealed that the free cisplatin, DOX, and CPT were found to be antagonistic to each other. Dual drug-loaded vesicles exhibited synergistic cancer cell killing while delivering these antagonistic drugs from a dextran vesicular platform. Remarkable synergistic cell killing was accomplished in cisplatin, DOX, and CPT triple drug-loaded vesicles at nanogram concentrations in breast cancer cells. The internalization of drugs and cellular uptake were confirmed by confocal microscope and flow cytometry analysis. The drugs were taken by the cancer cells in large amounts while delivering them from dextran vesicles compared to their free form. These spectacular results opened new opportunities for synergistic cancer therapy for GSH-overexpressed breast cancer using triple drug-loaded polysaccharide vesicular nanocarriers.